



L-Carnitine: a nutritional modulator of the glucocorticoid receptor

Salvatore Alesci, M.D., Ph.D.

CNE/NIMH & PREB/NICHD

National Institutes of Health

Bethesda, March 26, 2004

Glucocorticoids

Steroid hormones secreted by the adrenal gland basally, and increasingly in response to stress

Key regulators of carbohydrate, lipid and protein metabolisms


Potent anti-inflammatory and immunomodulatory effects

Essential for the normal functioning of the central nervous system, and the maintenance of cardiovascular, metabolic and immune homeostases

Treatment of choice for many inflammatory, autoimmune and lymphoproliferative disorders

Physiologic and pharmacologic actions mediated by intracellular receptors, the glucocorticoid receptors (GRs)

Human Glucocorticoid Receptor



Chromosome 5

GR α cDNA



GR β cDNA




GR α



1

777



Glucocorticoid-like effects of L-Carnitine

Suppression of LPS-induced cytokine production in rodents

(Med. Inflamm. 2:S43-50, 1993; Br. J Cancer 72:1173-79, 1995)

Reduced *ex vivo* release of TNF α by *S. aureus*-stimulated human PMNCs

(Med. Inflamm. 2:S37-41, 1993)

Decreased serum TNF α levels in surgical and AIDS patients

(Med. Inflamm. 2:S33-36, 1993; Immunopharmacol. Immunotoxicol. 15:1-12, 1993)

Equal efficacy of L-Carnitine and betamethasone administered to pregnant rats in increasing the dipalmitoyl-phosphatidylcholine content of the fetal lung

(Pediatr. Res. 18:1246-52, 1984; J. Perinat. Med. 24:591-99, 1996)

Hypothesis

The Glucocorticoid-like effects of high L-Carnitine doses may be mediated via direct modulation of GR α function

Objective

To study *in vitro* the effect of L-Carnitine on:

GR α

Binding capacity


Cell trafficking

Transcriptional activity

Biological activity

Competitive Binding



HeLa



Saturation Binding

HeLa

No Car:	$B_{max} = 202.1 \pm 6.46$	$K_d = 8 \pm 0.633$
25 mM Car:	$B_{max} = 201.7 \pm 4.46$	$K_d = 11.8 \pm 0.696$
50 mM Car:	$B_{max} = 180.5 \pm 7.72$	$K_d = 14.0 \pm 0.919$
100 mM Car:	$B_{max} = 183.2 \pm 11.9$	$K_d = 23.0 \pm 2.100$






GR α -GFP translocation

0




15 min

30 min

Dex
(10^{-6} M)



L-Car
(50 mM)



Reporter Plasmids

MMTV:LUC





SV40: β -Gal



Promoter transcription

HeLa: MMTV



Reporter Plasmids

TAT3:LUC



pODL02:LUC




SV40: β -Gal




Promoter transcription

HeLa









Promoter transcription

CV-1: MMTV




Cytotoxicity assay





Cytotoxicity assay

HeLa



LPS-stimulated cytokine secretion

Human elutriated monocytes



L-Car (mM)	-	-	50	100	-	-	50	100
Dex (10 ⁻⁸ M)	-	+	-	-	-	+	-	-
RU 486 (10 ⁻⁶ M)	-	-	-	-	+	+	+	+


LPS (mM)	-	-	50	100	-	-	50	100
Dex (10 ⁻⁸ M)	-	+	-	-	-	+	-	-
RU 486 (10 ⁻⁶ M)	-	-	-	-	+	+	+	+

Summary

In vitro, high but non-cytotoxic concentrations of L-Carnitine are able to:

- ➔ *Compete with dexamethasone for binding to the GR α , reducing the affinity of this receptor for its native ligand*
- ➔ *Trigger nuclear translocation of GR α*
- ➔ *Stimulate the transcription of glucocorticoid-responsive promoters through GR α transactivation*
- ➔ *Suppress the release of TNF α and IL-12 from human elutriated monocytes in a GR α -dependent fashion*

Proposed model of GR modulation by L-Carnitine



Future Research

-  *Molecular and structural mechanisms of L-Carnitine → GR α interaction*
-  *Tissue specificity/selectivity of GR α modulation by L-Carnitine (muscle, bone, adipose tissue, neurons)*
-  *Effect of L-Carnitine metabolites (Acetyl-L-Carnitine, Propionyl-L-Carnitine, etc.) on GR α function*
-  *Effect of L-Carnitine and its metabolites on the activity of other steroid receptors (PR, MR, AR, etc.)*
-  *Studies in animal models of chronic inflammatory and autoimmune disorders*
-  *Clinical trials*
-  *Drug designing*

Acknowledgements



George P. Chrousos
Tomoshige Kino
Massimo U. De Martino
Marco Mirani



Philip W. Gold



Salvatore Benvenga
Francesco Trimarchi



Piero Orteca



Antonino Amato